JPRN-UMIN000050415
Recruiting
未知
Study aiming for individualized pharmacotherapy based on genetic polymorphism for cognitive decline in elderly breast cancer patients. - Study aiming for individualized pharmacotherapy based on genetic polymorphism for cognitive decline in elderly breast cancer patients
Aichi Cancer Center Hospital0 sites100 target enrollmentFebruary 22, 2023
ConditionsBreast Cancer
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Breast Cancer
- Sponsor
- Aichi Cancer Center Hospital
- Enrollment
- 100
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\) Person who has serious organ dysfunction and cannot receive chemotherapy treatment 2\) A person who has judged that incorporation into research is inappropriate
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Study for personalized medicine based on pharmacokinetics and pharmacodynamics concerned with therapeutic drug of nontuberculous mycobacterium.JPRN-UMIN000020406Center for Infectious Disease and Infection Control10
Not yet recruiting
Phase 1
Clinical study of Darvyadi Granules in Iron Deficiency Anaemia.Health Condition 1: D508- Other iron deficiency anemiasHealth Condition 2: D508- Other iron deficiency anemiasCTRI/2020/04/024459Parul University
Not yet recruiting
Phase 3
Arka dosage form of shweta Aparajita roots in management of Primary Hypothyroidism as add on along with Thyroxine.Health Condition 1: E039- Hypothyroidism, unspecifiedCTRI/2024/07/070645Dr Jayshree Hadke
Active, not recruiting
Phase 3
Clinical study to assess how well wilate works in the regular treatment of young children with severe von Willebrand diseaseISRCTN11217735Octapharma (Austria)12
Unknown
Phase 1
Clinical pharmacology study to investigate the food effect on pharmacokinetics of TAS-102.Patients with solid tumorJPRN-jRCT2080221443Taiho Pharmaceutical Co., Ltd.16